Bio Green Med Solution, Inc. filed a current report on Form 8-K on November 4, 2026, disclosing that it received a written notice from Nasdaq on October 29, 2026, stating its common stock had failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days.

Key Highlights

  • Nasdaq notice received October 29, 2026: The company's common stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days.
  • 180-day compliance window: The company has until April 27, 2027, to regain compliance with the minimum bid price requirement.
  • Compliance path: Compliance can be regained if the closing bid price of the common stock is at or above $1.00 per share for a minimum of 10 consecutive business days before April 27, 2027.
  • No immediate trading impact: According to the filing, the notice has no immediate effect on the listing or trading of the common stock, which continues to trade under the symbol "BGMS."
  • Reverse stock split under consideration: A stockholder proposal for a reverse stock split at a ratio between 1:4 and 1:16 was included in a Form S-4 declared effective by the SEC on October 8, 2026.
  • Pending business combination: The company entered into a Business Combination Agreement on June 4, 2026, with Future NRG Sdn. Bhd., a Malaysia private limited company, which would result in FNRG becoming a wholly owned subsidiary.

Bio Green Med Solution Discloses Nasdaq Bid Price Deficiency and Compliance Options

According to the Form 8-K filed with the SEC, Bio Green Med Solution, Inc. (NASDAQ:BGMS) received a written notice from Nasdaq Stock Market LLC on October 29, 2026, notifying the company that its common stock, par value $0.001 per share, had failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, as required under Nasdaq Listing Rule 5550(a)(2). The notice triggered an automatic 180 calendar-day grace period running through April 27, 2027.

The filing states that the notice has no immediate effect on the listing or trading status of the common stock, and shares will continue to trade on The Nasdaq Capital Market under the symbol "BGMS." The company disclosed that it will regain compliance if the closing bid price equals or exceeds $1.00 per share for at least 10 consecutive business days before the deadline. If the company does not regain compliance within the allotted period, including any extensions Nasdaq may grant, the filing states that "Nasdaq will provide notice that the Common Stock will be subject to delisting from The Nasdaq Capital Market," at which point the company may appeal to a hearings panel.

The company disclosed it intends to monitor bid price levels and "will consider appropriate alternatives to achieve compliance within the initial 180 calendar-day compliance period, including, among other things, a potential reverse stock split, as part of the closing of the Transaction." The pending Transaction refers to the Business Combination Agreement entered into on June 4, 2026, with Future NRG Sdn. Bhd. and its shareholders. A related Form S-4 registration statement, which included a reverse stock split proposal at a ratio of not less than 1:4 and not more than 1:16, was declared effective by the SEC on October 8, 2026. The filing notes that "there can be no assurance" that stockholders will vote in favor of the reverse split proposal or that compliance will be achieved. The filing contains forward-looking statements that are the company's own and subject to its cautionary language.

What Was Disclosed

Bio Green Med Solution, Inc. disclosed receipt of a Nasdaq minimum bid price deficiency notice dated October 29, 2026, triggering a compliance deadline of April 27, 2027, while noting a pending business combination with Future NRG Sdn. Bhd. and a potential reverse stock split as compliance options.